Clinical trials: Irinotecan
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- CRYSTAL (NCT00154102)
- Testing
- Cetuximab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- Where
- 154 sites in Argentina, Australia and 28 more
- Volunteers
- 1,221 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens
The primary objective of the study is to determine whether there is a correlation between the intestinal side effects of chemotherapy treatment and the expression/activity profiles of glucuronidase enzymes in the stool microbiome…
- Trial name
- NCT05821582
- Testing
- Stool Collection and Survey Completion
- Where
- United States
- Sponsor
- Sanguine Biosciences
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Advanced Solid Tumors
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy…
- Trial name
- NCT06741644
- Testing
- CS2009, Pemetrexed, Carboplatin
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 800 people
- Sponsor
- CStone Pharmaceuticals
Colorectal Cancer
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer.
- Trial name
- NCT00047762
- Testing
- Erlotinib (aka Tarceva or OSI-774), Bevacizumab (aka Avastin or Rhu MAb VEGF)
- Where
- 3 sites in United States
- Sponsor
- Genentech, Inc.
Unresectable or Metastatic Colorectal Cancer
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients
- Trial name
- NCT00668863
- Testing
- FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil), Sunitinib
- Where
- 10 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Pfizer
Pancreatic Cancer
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic…
- Trial name
- NCT07444541
- Testing
- ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Anova Innovation Limited
Cancer, Neoplasms
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
IT141 is a novel nanoparticle formulation of SN-38, the active metabolite of irinotecan, and is intended to deliver more drug to the tumor with reduced toxicity on normal tissues.
- Conditions
- Cancer, Neoplasms, Tumors, Refractory Solid Tumors
- Trial name
- NCT03096340
- Testing
- IT-141
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Intezyne Technologies, Inc.
Advanced Colorectal Cancer
A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer
This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.
- Trial name
- NCT04337879
- Testing
- AL2846, Calcium folate, 5-FU
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Adenocarcinoma
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.
- Trial name
- NCT06951503
- Testing
- AK112, Oxaliplatin, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 560 people
- Sponsor
- Akeso
Colorectal Neoplasms, Neoplasm Metastasis
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal cancer.
- Trial name
- NCT00921661
- Testing
- AVE0005 (aflibercept)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Sanofi
Pancreatic Adenocarcinoma
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have…
- Trial name
- Trybeca-1 (NCT03665441)
- Testing
- eryaspase, Gemcitabine plus Abraxane, Irinotecan plus 5-FU plus leucovorin
- Where
- 16 sites in United States, France and 1 more
- Volunteers
- 512 people
- Sponsor
- ERYtech Pharma
Advanced Solid Tumor
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX…
- Trial name
- NCT00502567
- Testing
- AZD2171, FOLFOX, Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Colorectal Neoplasm
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
The purpose is to characterise the tolerability of Modufolin (arfolitixorin) in combination with 5-FU alone, in combination with 5-FU and Oxaliplatin, in combination with 5-FU and Irinotecan and in combination with 5-FU…
- Trial name
- NCT02244632
- Testing
- Modufolin (arfolitixorin), Fluorouracil, Oxaliplatin
- Where
- 10 sites in Denmark, Greece and 2 more
- Volunteers
- 105 people
- Sponsor
- Isofol Medical AB
Advanced Solid Tumor
Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
This is a Phase I, open-label, non-randomized, dose-escalation study to evaluate the safety and tolerability, the maximum tolerated dose (MTD) and the dose limited toxicity(DLT) of LY01610 monotherapy and combine with 5-Fu in…
- Trial name
- NCT04088604
- Testing
- LY01610 ( Irinotecan hydrochloride liposome injection ), LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）, Irinotecan Hydrochloride Injection（CAMPTO®）
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Luye Pharma Group Ltd.
Advanced Solid Tumors
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
The Phase Ib study was designed to evaluate the safety of JS109 in combination with irinotecan in the treatment of advanced solid tumors and to determine the Phase II recommended dose (RP2D).
- Trial name
- NCT05824455
- Testing
- JS109 combine with irinotecan
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Metastatic Colorectal Carcinoma
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI.
- Trial name
- NCT01937715
- Testing
- PF-05212384, FOLFIRI regimen, Bevacizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 18 people
- Sponsor
- Pfizer
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
In this study, participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that had progressed after first-line…
- Trial name
- NCT02564263
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Volunteers
- 628 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
This is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation.
- Trial name
- NCT03288987
- Testing
- Bevacizumab + FOLFIRI-3
- Where
- 22 sites in Iran
- Volunteers
- 126 people
- Sponsor
- AryoGen Pharmed Co.